Human Pancreatic Cancer Non-Invasive Diagnostics
NISTA: a novel non-invasive, data-enabled ML tool enabling earlier and more accurate diagnosis of pancreatic cancer, stratifying patients into more personalised treatment pathways to improve outcomes.
Dates
December 2023 – November 2025
Description:
PROJECT OBJECTIVE:
In this 24-month Industrial-Research project, EosDx will collaborate with Ulster University to conduct prototype development, optimizing NISTA for pancreatic tissue analysis, and combining histological and X ray diffraction (XRD) data to develop rapid pancreatic cancer molecular stratification.
Key project outputs include:
● NISTA optimized for pancreatic tissue analysis
● Model for identification of development stage/subtype of pancreatic cancer (de-novo taxonomy)
● 3D-mapsofpancreatic cancer tumors extensions based on subtype
Rationale:
The potential for the novel EoSDx technology to impact and address clinical issues associated particularly with pancreatic cancer is easily demonstrable. Pancreatic tumors form and develop through a highly desmoplastic microenvironment and this feature is a major cause of the aggressive nature and therapeutic resistance of pancreatic cancer. The EoSDx technology specifically characterizes the components of this type of matrix with a high specificity thus offering opportunities for early prognoses and potential targeted therapy pathways.